Ultragenyx Pharma (RARE) PT Raised to $39 at Cantor Fitzgerald on FAYUVI Approval

September 18, 2026 7:01 AM

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $39.00 (from $33.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found